To the Editor
Patient | WHO | IPSS | Serum Ferritin | Transfusion therapy | Transfusional dependent | WPSS |
---|---|---|---|---|---|---|
1
| RA | NA | 288,8 | No transfusion therapy | NO | NA |
2
| RAEB 2 | INT 1 | 94,7 | No transfusion therapy | NO | HIGH |
3
| RCMD | INT 1 | 416,5 | 14 RCC | NO | LOW |
4
| RARS | INT 1 | 1.994,0 | 69 RCC | Yes | LOW |
5
| RA | NA | 826,0 | No transfusion therapy | NO | NA |
6
| RA | LOW | 22,4 | No transfusion therapy | NO | LOW |
7
| MDS-T | NA | 3.484,0 | 42 RCC | Yes | NA |
8
| RARS | NA | 1.399,0 | 64 RCC | Yes | NA |
9
| RCMD | NA | 7.107,0 | 81 RCC | Yes | NA |
10
| RARS | LOW | 1.587,0 | 20 RCC | Yes | LOW |
11
| RARS | INT 1 | 132,0 | 04 RCC | NO | INT |
12
| RARS | LOW | 1.937,8 | 82 RCC | Yes | LOW |
13
| RARS | NA | 541,0 | No transfusion therapy | NO | NA |
14
| RA | LOW | 307,0 | No transfusion therapy | NO | VERY LOW |
15
| RCMD | INT 1 | 5.113,1 | 96 RCC | Yes | INT |
16
| RCMD | LOW | 38,0 | No transfusion therapy | NO | LOW |
17
| RCMD | NA | 98,0 | 03 RCC | NO | NA |
18
| RARS | LOW | 318,0 | No transfusion therapy | NO | VERY LOW |
19
| RCMD | LOW | 87,0 | No transfusion therapy | NO | LOW |
20
| RCMD | NA | 765,0 | 38 RCC | Yes | NA |
21
| RCMD | INT 1 | 780,0 | 17 RCC | Yes | HIGH |
22
| RARS | LOW | 356,2 | No transfusion therapy | NO | VERY LOW |
23
| RCMD | INT 1 | 298,4 | No transfusion therapy | NO | LOW |
24
| RCMD | INT 1 | 2.160,0 | 24 RCC | Yes | HIGH |
25
| RA | LOW | 86,4 | No transfusion therapy | NO | VERY LOW |
26
| RCMD | NA | 276,0 | No transfusion therapy | NO | NA |
27
| RCMD | NA | 1.922,3 | 24 RCC | Yes | NA |
28
| RAEB 2 | INT 2 | 1.022,0 | 42 RCC | Yes | VERY HIGH |
29
| RARS | NA | 321,0 | No transfusion therapy | NO | NA |
30
| RCMD | NA | 223,0 | 12 RCC | Yes | NA |
31
| RAEB 1 | INT 1 | 229,0 | 03 RCC | NO | VERY LOW |
32
| RCMD | INT 1 | 132,4 | No transfusion therapy | NO | INT |
33
| RCMD | NA | 556,0 | 04 RCC | NO | NA |
34
| RCMD | NA | 850,0 | 10 RCC | NO | NA |
Controls(14)
|
NT-MDS(21)
|
T-MDS(13)
|
P value
| |
---|---|---|---|---|
Baseline demographics and characteristics
| ||||
Age (year)
| 72.4 ± 8 (58–84) | 70.3 ± 14 (47–88) | 65.2 ± 20 (27–90) | NS |
Gender (m/f)
| (6/8) | (7/14) | (6/7) | |
Body weigth (kg)
| 66.0 ± 11.9 (46 – 83) | 63.7 ± 10.1 (43.6 – 91.3) | 64.9 ± 10.1 (49.3 – 90) | NS |
Height (m)
| 1.59 ± 0.09 (1.45 – 1.75) | 1.57 ± 0.07 (1.46 – 1.72) | 1.59 ± 0.08 (1.45 – 1.70) | NS |
BSA (m
2
)
| 1.68 ± 0.16 (1.42 – 1.98) | 1.64 ± 0.15 (1.33 – 2.01) | 1.67 ± 0.15 (1.4 – 2.01) | NS |
BMI (kg/m
2
)
| 26.2 ± 5.7 (19.1 – 36.9) | 25.8 ± 2.9 (20.5 – 32.3) | 25.5 ± 3.7 (21.4 – 32.7) | NS |
HR (bpm)
| 75.8 ± 5.4 (66–83) | 77.6 ± 1.4 (66–88) | 78.4 ± 2.2(65–90) | NS |
SBP (mmHg)
| 139.2 ± 19 (110–180) | 121.8 ± 16 (100–150) | <0.02 | |
DBP (mmHg)
| 77.9 ± 12 (60–108) | 70 ± 9.6 (60–90) | NS | |
Hb (g/dL)
| 9.85 ± 1.8 (6.6 - 12.7) | 6.5 ± 1.7 (3.8 - 9.9) | <0.001 | |
Ferritin (ng/mL)
| 298.8 ± 234 (22.4 a 850) | 2269 ± 1931 (223 a 7101) | <0.001 | |
Chamber quantification and ejection fraction of patients and controls
| ||||
LVDD (mm)
|
46.0 ± 4.7 (40–57)
|
48.5 ± 3.9 (41–56)
|
49.3 ± 6.6 (40–64)
|
NS
|
LVSD (mm)
|
26.9 ± 4.9 (19–39)
|
27.7 ± 3.7 (22–37)
|
29.5 ± 6.8 (23–50)
|
NS
|
IVS (mm)
|
8.9 ± 2.3 (6–16)
|
8.5 ± 0.9 (7–11)
|
8.9 ± 1.4 (7–12)
|
NS
|
LVPW (mm)
|
8.5 ± 1.7 (6–13)
|
8.4 ± 0.7 (7–10)
|
8.8 ± 1.4 (7–12)
|
NS
|
MASS (g)
|
165.9 ± 61,0 (79–326)
|
173.8 ± 34.1 (116–249)
|
165.9 ± 61.0 (90–321)
|
NS
|
MASS index (g/m
2
)
|
101.3 ± 37 (55.6 - 185)
|
106 ± 18 (73–140.7)
|
110 ± 37.1 (56.2 - 198)
|
NS
|
EF%TEI
|
71.8 ± 7.6 (58.2 - 89)
|
71.9 ± 6.5 (58.8 - 80.1)
|
69.8 ± 9.3 (43.6 - 83.9)
|
NS
|
FS (%)
|
41.4 ± 6.8 (31.2 - 58)
|
41.6 ± 5.7 (31–48.7)
|
39.4 ± 7.2 (22–53)
|
NS
|
LA (mm)
|
32 ± 4.2 (27–44)
|
33.4 ± 4.2 (28–43)
|
36.5 ± 4.9 (31–46)
|
<0.04*
|
EF%SIM
|
67.7 ± 7.3 (50.1 - 81.3)
|
66.2 ± 4.8 (55.2 - 76.1)
|
64.7 ± 5.4 (50.7 - 70.8)
|
NS
|
LVEDV (ml)
|
65.5 ± 18 (37–105)
|
85.1 ± 29.9 (44–169)
|
92.8 ± 36.1 (49–189)
|
<0.05*
|
LVESV (ml)
|
20.5 ± 6.2 (10–28)
|
28.7 ± 11.9 (12.5 - 65)
|
33.8 ± 19.7 (15–93)
|
<0.04*
|
LAV (ml)
|
39.1 ± 14.5 (17–69)
|
43.5 ± 10.3 (25–64)
|
59.8 ± 24.8 (29–120)
|
<0.006**
|
LAV index (mL/m
2
)
|
22.8 ± 8 (10.5 - 39.6)
|
26.5 ± 5.2 (15.9 - 34.8)
|
35.9 ± 15 (18.8 - 70.9)
|
<0.004**
|
Doppler parameters (transmitral and myocardial tissue) and strain of patients and controls
| ||||
Evel(cm/s)
| 77.2 ± 13.2 (55.4 - 105) | 89.6 ± 20 (63–128) | 96.6 ± 14.2 (68.5 - 116) | <0.02* |
Avel(cm/s)
| 94.3 ± 18 (68.6 - 137.3) | 100.2 ± 19 (68.5 - 131) | 100.6 ± 27 (52.8 - 145) | NS |
E/A
| 0.83 ± 0.2 (0.6 - 1.2) | 0.9 ± 0.2 (0.6 - 1.4) | 1.0 ± 0.26 (0.64 - 1,6) | NS |
Em(cm/s)
| 8.6 ± 3.2 (4.1 - 14) | 9.3 ± 2.4 (5.4 - 14) | 10.4 ± 2.5 (7.5 a 14.8) | NS |
E/Em
| 10 ± 3.4 (5.3 - 16.2) | 10.3 ± 3,9 (5.6 - 20) | 9.7 ± 2.9 (5.9 - 14.4) | NS |
LV-Sm(cm/s)
| 6.5 ± 1.3 (5.1 - 9.5) | 7.9 ± 1.3 (5.5 - 10.8) | 7.8 ± 1.3 (6–10,3) | <0.02* |
RV-Sm(cm/s)
| 10.1 ± 0.7 (9.1 - 11) | 11.4 ± 3.3 (7.6 - 19) | 12.3 ± 1,5 (9.8 - 14,7) | NS |
TAPSE(mm)
| 24.9 ± 4.2 (20–33) | 28.2 ± 5.3 (21–39) | 28.9 ± 5 (22–40) | NS |
VD basal(mm)
| 30.1 ± 6.4 (22–48) | 31.7 ± 4 (24–41) | 31.5 ± 4 (23–39) | NS |
ST2DL (%)
| −19.9 ± 2.7 (−24 to −13) | −20.7 ± 2.5 (−25 to −16,8) | −20.9 ± 1.4 (−23 to - 18,6) | NS |